CoQ10 CF (100mg) (60 Softgels)


CoQIO CF 100 is an all-natural, proprietary, patent-pending, crystal/solvent-free, lipid-stabilized CoQW shown in recent clinical trials to be more than eight times as absorbable as powdered forms of CoQW and more than twice as bioavailable as oil-based or “nano” formulas. CoQIO CFIOO’s proprietary monoglyceride carrier is a patent-pending formulation unmatched for optimal utilization in the support of cardiovascular, CNS, immune, and energy-based health needs.
All Arthritis Center Of Riverside® Formulas Meet or Exceed cGMP quality Standards.
Take one to two softgels daily, with meals, or as directed by your healthcare practitioner.
Consult with your healthcare practitioner before use. Keep out of reach of children.
SKU: 1006 Category:


Coenzyme Q10 is a biologically active, natural vitamin-like substance belonging to a group of compounds called ubiquinones. Structurally similar to vitamin K, it is present in animal protein and can be synthesized in the body. However, a variety of factors, including aging, may cause a CoQ 10 deficiency.
Despite its poor absorption (0.6-1.0%), pure crystalline (powdered) CoQ10 was the industry standard from the 1970’s to the mid-1990’s. A variety of forms and delivery systems offering somewhat improved absorption (2.3-5%) have entered the market since 1995; however, these forms have been unstable and crystallized, making them difficult or impossible for the body to absorb.
CoQ10 CF 100 represents a new generation of CoQ10 supplements. Unlike many others in today’s market place, it is crystal-free when examined by a light microscope. This patent-pending formulation contains three lipids to aid in dissolving CoQ10 crystals into single molecules, stabilizing the formula to prevent re-crystallization, and facilitating passive diffusion to enhance absorption.
A full double-blind, randomized clinical trial in twenty normal human volunteers with a relatively controlled diet was performed to determine the absorption and steady-state bioavailability characteristics. Absorption involves several phases in the movement of CoQ10 through a portion of the digestive tract, into the lymphatics, and into general circulation, where it becomes bioavailable. Absorption is reflected by the time base changes in the amount of CoQ10 appearing in the blood plasma after the ingestion of a single known dose. Bioavailability refers to the amount of CoQ10 accumulated in the blood plasma over an extended time after taking a known constant daily dose.
Within the trial, a 36-hour absorption study showed thatCoQIO CF 100 had a total absorption 783% greater than powdered CoQ10 (11.65% vs 1.32%). The bioavailability study measured blood accumulation (mg) of CoQ 10 over 28 days. The 28-day steady-state bioavailability for CoQ10 CF 100 was 8.86 mg, compared to 1.64 mg for the dry powder standard. The relative bioavailability showed that CoQ10 CF 100 was 541% more bioavailable than the standard product. The AUC (0-28 day) was 680 mg/day compared to 120 mg/day or 463% more bioavailable than the dry powder standard.
CoQ10 CF 100 is titanium dioxide-free, making the softgel transparent and permitting verification of the crystal-free claim.
1.  Berthold al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomized trial. Drug Saf. 2006;29(8):703-12 [PMID: 16872244]
2.  Lopez-Lluch G, Barroso MP, Martin SF, Fernandez-Ayala DJ, Gomez-Diaz C, Villalba JM, Navas P. Role of plasma membrane coenzyme Q on the regulation of apoptosis. Biofactors. 1999;9(2-4):171 [PMID: 10416029]
3.  Crane FL Biochemical functions of coenzyme Q10. J Am Coll Nutr. 2001 Dec;20(6):591-8
4.  Rundek T, Naini A, Sacco R, Coates K, DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke./Irch Neuro/. 2004 Jun;61(6):889-92 [PMID: 15210526]
5.  Littarru GP, Lippa S, Oradei A, Serino F.Coenzyme Q10: blood levels and metabolic demand. Int J Tissue React. 1990;12(3):145-8. [PMID: 2276891]
6.  Munkholm H, Hansen HHT, Rasmussen K: Coenzyme Q10 treatment in serious heart failure. Biofactors 1999;9(2-4): 285-289 [PMID: 10416042]
7.  Eriksson JG, Forsen TJ, Mortensen SA, Rohde M: The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. Biofactors 1999: 315-318 [PMID: 10416046]
8.  Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors. 1999; 9(2-4): 273-84. [PMID:10416041]
9.  Rosenfeldt F, Hilton D, Pepe S, Krum H Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors. 2003;18(1-4):91-100 [PMID: 14695924]
9.    Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: an update. CurrOpin Clin Nutr Metab Care. 2005 Nov;8(6):641-6. Review. [PMID: 16205466]
10.    de Lau LM. Serum cholesterol levels and the risk of Parkinson’s disease. Am J Epidemiol. 2006 Nov 15;164(10):998-1002. Epub 2006 Aug [PMID: 16905642]
Figuero E,et al. Oxidant/antioxidant interactions of nicotine, Coenzyme Q10, Pycnogenol and phytoestrogens in oral periosteal fibroblasts and MG63 osteoblasts.
Steroids. 2006 Dec;71(13-14):1062-72. Epub2006 Oct 11 [PMID: 17045317]
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or 
prevent any disease.